Lapatinib, which targets EGFR and ErbB-2, is being examined in both a phase 0 study treating vestibular schwannomas (NCT00863122) and a phase II (NCT00973739) trial for its effectiveness in all NF2 related tumor types. This evidence concerns the gene EGFR and Vestibular schwannoma.